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See Article, pages 93–101Over the past 20 years, there has been a dramatic increase in the
prevalence of obesity in most Western and some developing
countries. In fact, the proportion of obese adults is now 34.9%
in the US population [1] and 14.5% in the French population
[2]. Several genes have been identiﬁed to be associated with
the development of obesity in various animal models; in addition
abnormal neural pathways have been proposed that may impact
the regulation of energy balance, as well as innate and acquired
immune activation in adipose tissue. These mechanisms do not
account for the entirety of the obesity epidemic and clearly life-
style choices including increased caloric intake, especially in fat,
and low physical activity contribute to the increase in obesity.
In turn, obesity has been noted to have adverse health implica-
tions such as a reduction in sleep duration, disruption of
circadian rhythm, and an increased risk of diabetes [3]. Obesity-
associated type 2 diabetes mellitus not only increases the risk
of cardiovascular complications, but also the risk of cancer and
cancer-related mortality, especially hepatobiliary cancer [4,5].
The so-called metabolic syndrome (MetS) involves a sub-
group of obese patients and is deﬁned by the association of: i)
central obesity with increased waist circumference; ii) increased
fasting glucose; iii) increased blood pressure; iv) reduced HDL
cholesterol; and v) increased triglycerides [6]. This condition is
associated with a high risk of non-alcoholic fatty liver disease
(NAFLD), which is the hepatic consequence of insulin resistance,
with accumulation of triglycerides into hepatocytes. Roughly,
25% of patients with NAFLD will end up developing non-alcoholic
steatohepatitis (NASH) [7], which in turn may lead to cirrhosis
and hepatocellular carcinoma (HCC). MetS-associated HCC can,
however, develop without signiﬁcant ﬁbrosis in the underlying
liver [8]. In particular, NAFLD, obesity, and type 2 diabetes are
independent risk factors for HCC, and may mutually potentiate
the risk of liver malignancy. The epidemiology of this new emer-
gent source of HCC is not fully described yet. In most series of
patients with HCC, the prevalence of NAFLD-related HCC ranges
from 4% to 22% [9], however the incidence is expected to increase
in the future considering the obesity epidemic worldwide.Journal of Hepatology 20
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Italy sought to compare results of liver resection for HCC related
to the MetS (MetS-HCC) and hepatitis C-related HCC (HCV-HCC)
[10]. Speciﬁcally, the authors compared the postoperative course
and long-term outcome of 96 MetS-HCC patients undergoing
liver resection over 13 years to the outcome of 96 matched
HCV patients undergoing liver resection during the same period.
The reported characteristics of both tumor and background liver
were in accordance with previous surgical series, i.e. isolated
large sized well/moderately differentiated lesions occurring in
the setting of a rarely severely ﬁbrotic/cirrhotic underlying par-
enchyma [11]. In this setting, the authors observed that liver
resection for MetS-HCC was associated with a similar postopera-
tive course with identical rates of overall, major, liver speciﬁc and
cardio-respiratory postoperative complications as matched HCV
controls. In particular, the postoperative morbidity was compara-
ble in both groups of patients. These data are in agreement with
some previous publications from large academic medical centers
that have examined cohorts of patients with steatosis and meta-
bolic syndrome, which similarly noted the safety of modern day
liver surgery among patients with obesity. However, other popu-
lation data from the United States have suggested a higher inci-
dence of complications among patients at the extreme of body
mass index, even after adjusting for other clinical factors.
Speciﬁcally, when examining large numbers of patients (i.e.,
n >2000), several authors have reported a near two-fold increase
risk of complications among patients with obesity and MetS
[12,13]. Data from the current study by Vigano, therefore, need
to be interpreted cautiously. The overall number of patients
included in the study was small (n = 96), patients were well-se-
lected (only 6.1% of overall liver resections), and the surgical pro-
cedures were performed at 1 of 6 high volume HPB units. In light
of these limitations, as well as the population based data that are
at odds with the data from Vigano et al., whether the risk of peri-
operative morbidity is truly comparable in MetS vs. non-MetS
patients in the ‘‘general surgical community’’ remains undeﬁned.
Regarding long-term results of liver resection for MetS-HCC,
the data from Vigano et al., are also somewhat difﬁcult to inter-
pret. The authors conclude that MetS-associated HCC correlates
with excellent long-term results, better than HCV-HCC. The over-
all survival among patients with MetS HCC vs. non-MetS HCC was
actually quite comparable (65.6% vs. 61.4%), with a marginal15 vol. 63 j 8–9
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p value of 0.031. As such, a more conservative – and perhaps
more appropriate – conclusion would be that long-term outcome
was no different among patients with MetS HCC. In addition, of
this particular note, the comparison of MetS HCC vs. HCV-HCC
was made using a subgroup of HCV patients with a low preva-
lence of cirrhosis, which is uncommon. In other studies, overall
and disease-free survivals were no different between MetS-HCC
patients and those with HCC occurring on alcoholic or crypto-
genic cirrhosis [14]. Long-term results of patients with MetS
may be inﬂuenced by treatment of the different components of
the metabolic syndrome aimed at reducing the cardiovascular
complications, as well as mortality related to diabetes, etc. In
the current study, Vigano and colleagues provide data to suggest
that cancer speciﬁc recurrence-free survival was better among
MetS patients – although again the difference was marginal
(p = 0.077). Furthermore, interpreting recurrence data against a
control population of HCV patients – who have traditionally been
at a very high risk of recurrence – does not allow us to fully
understand the risk of recurrence among MetS patients vs. other
HCC patients (e.g. alcoholic HCC, HBV HCC, etc.). Moreover, it is
difﬁcult to analyze precisely the risk of HCC recurrence, which
depends upon the tumor aggressiveness and presence of underly-
ing cirrhosis (absent in most patients of Vigano’s series) in HCV
patients, and on underlying NAFLD and systemic inﬂammation
due to obesity and insulin resistance in MetS patients. The sug-
gestion of improved recurrence-free survival should not dissuade
providers from maintaining a rigorous surveillance program for
patients with MetS. MetS remains an important risk factor for
both de novo and recurrent HCC, with an increased risk of HCC
as high as 40–50% over baseline populations [15]. In turn, MRI
should probably be the modality of choice, as the accuracy of this
modality is better than CT imaging in the setting of a steatotic
liver [16,17].
While Vigano and colleagues should be congratulated for
helping to shed light on the important topic of MetS-associated
HCC, further studies are necessary. The current study, although
accumulated experience of 6 major centers, still suffers from
small sample size characterized by data with wide 95% conﬁ-
dence intervals and lack of statistical power. For example,
whether the lack of ﬁnding an association between steatohepati-
tis and outcome was ‘‘real’’ or due to a lack of power (only 24
patients had steatohepatitis among patients with MetS) remains
to be seen – especially in light of other studies that have noted a
negative effect of steatohepatitis [18–20]. Unfortunately, as the
epidemic of obesity increases, MetS-HCC will be a much more
common indication for surgical evaluation. Data from the current
study conﬁrm that resection will be central to the treatment of
these patients.Conﬂict of interest
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